COMPASS Pathways
CMPS · Nasdaq · United Kingdom
Share price · CMPS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CMPS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 2 Nov 2026-27.3%
- 9 Sep 2026+8.0%
Nothing announced by CMPS that day or the session before.
- 5 Aug 2026+15.1%
- 13 May 2026+17.0%
- 20 Apr 2026+42.0%
Nothing announced by CMPS that day or the session before.
- 16 Apr 2026+11.7%
Nothing announced by CMPS that day or the session before.
- 17 Feb 2026+31.3%
- 4 Dec 2025+11.6%
Nothing announced by CMPS that day or the session before.
Share of unusual movement by asset
For each asset, the share of CMPS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | 5-HT2A receptorSmall molecule | Major Depressive DisorderPost-Traumatic Stress Disorder |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
November 2028 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $23M | $444M | $9.8M-$51M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $29M | $434M | $254M-$40M operating cash flow | report ↗ |
| 2026-Q1 | — | $26M | $466M | —-$48M operating cash flow | report ↗ |
| 2025-Q3 | — | $27M | $186M | $138M-$35M operating cash flow | report ↗ |
| 2025-Q2 | — | $30M | $222M | $38M-$39M operating cash flow | report ↗ |
| 2025-Q1 | — | $31M | $260M | $18M-$46M operating cash flow | report ↗ |
| 2024-Q3 | — | $33M | $207M | $39M-$22M operating cash flow | report ↗ |
| 2024-Q2 | — | $29M | $229M | $38M-$34M operating cash flow | report ↗ |
| 2024-Q1 | — | $25M | $263M | $35M-$21M operating cash flow | report ↗ |
| 2023-Q3 | — | $22M | $248M | $33M-$17M operating cash flow | report ↗ |
| 2023-Q2 | — | $20M | $148M | $28M-$25M operating cash flow | report ↗ |
| 2023-Q1 | — | $19M | $117M | $24M-$28M operating cash flow | report ↗ |
| 2022-Q3 | — | $14M | $173M | $18M-$19M operating cash flow | report ↗ |
| 2022-Q2 | — | $16M | $207M | $21M-$18M operating cash flow | report ↗ |
| 2022-Q1 | — | $15M | $244M | $21M-$23M operating cash flow | report ↗ |
| 2021-Q3 | — | $12M | $294M | $16M-$14M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $118M | $150M | $72M-$157M operating cash flow | report ↗ |
Revenue was not disclosed. R&D spend was $118.44M, down 0.5% YoY, and cash and equivalents were $149.99M. The company reported a net loss of $287.86M, with a quarterly net burn of $287.86M.
The company expects its cash position at March 24, 2026 to fund operations into 2028. It plans to meet with the FDA to confirm a rolling NDA submission for COMP360 in treatment-resistant depression, expects to complete the NDA submission in Q4, and anticipates 26-week Part B data from COMP006 in early Q3 2026. A Phase 2b/3 PTSD trial is initiating after FDA acceptance of the IND, commercial readiness is being advanced for launch by the end of 2026, and a $150M February financing plus $200M warrant exercise extended the cash runway.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-03 | Nath Kabir · director, Chief Executive Officer | Tax withholding | 5,962 | $11.25 | $67K | Form 4 |
| 2026-05-27 | Tregoning Kathleen · director | Award / grant (derivative) | 41,119 | — | — | Form 4 |
| 2026-05-27 | Norton David Y · director | Award / grant (derivative) | 21,110 | — | — | Form 4 |
| 2026-05-27 | McQuade Robert · director | Award / grant (derivative) | 21,110 | — | — | Form 4 |
| 2026-05-27 | Riley Wayne Joseph · director | Award / grant (derivative) | 21,110 | — | — | Form 4 |
| 2026-05-27 | JONAS JEFFREY M · director | Award / grant (derivative) | 21,110 | — | — | Form 4 |
| 2026-05-27 | Gover Justin D. · director | Award / grant (derivative) | 21,110 | — | — | Form 4 |
| 2026-05-27 | SANTINI GINO · director | Award / grant (derivative) | 30,158 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 190 reporting institutions held 93.3M shares ($514.8M, 69.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Deep Track Capital, LP | 12,161,496 | $67.3M |
| 2 | RTW INVESTMENTS, LP | 10,632,390 | $58.8M |
| 3 | MARSHALL WACE, LLP | 4,038,335 | $22.3M |
| 4 | TANG CAPITAL MANAGEMENT LLC | 4,002,200 | $22.1M |
| 5 | BIT Capital GmbH | 3,491,234 | $19.3M |
| 6 | ARK Investment Management LLC | 3,301,050 | $18.3M |
| 7 | MILLENNIUM MANAGEMENT LLC | 3,138,522 | $17.4M |
| 8 | GMT Capital Corp | 3,078,536 | $17.0M |
| 9 | TWO SIGMA INVESTMENTS, LP | 2,583,499 | $14.3M |
| 10 | DAFNA Capital Management LLC | 2,418,882 | $13.4M |
| 11 | BAKER BROS. ADVISORS LP | 2,344,720 | $13.0M |
| 12 | Eagle Health Investments LP | 2,060,427 | $11.4M |
| 13 | NEXTBio Capital Management LP | 2,021,407 | $11.2M |
| 14 | UBS Group AG | 1,855,070 | $10.3M |
| 15 | Kalehua Capital Management LLC | 1,639,384 | $9.1M |